And natural poisons. These inhibitors alter the functioning of enzymes and thus altering the gene
expression. Few other important applications such as male erectile dysfunction, survival of bacterial
pathogens, blocking specific protein in the pancreas, regulation of neurological functioning, and
stopping toxins that pollutes environment are expected to drive the market in the near future.
Few factors that are expected to thrust the market of enzyme inhibitor are research & development
spending by pharmaceutical companies, increasing competition, and technological advancement.
Upcoming new technologies have led to the new product development, which has assisted the market
to expect high growth over the forecasted period. Sedentary lifestyle, pandemic threats, and higher
risk of disease are few other driving factors that will fuel in the growth of the market by 2022. The
key restrain that may slightly decrease the revenue growth of the market is due to the patent
expiration. Last few years patent expiration has led the pharmaceutical industry to bear revenue
losses of more than USD 20 billion each year, but from the strategic actions by pharmaceutical
companies it is projected to go down to less than one third.
The market is segmented by reversible and irreversible as per the inhibitors binding with the enzymes.
Reversible inhibitor binding with enzyme is created through non-covalent bonding such as ionic bonds
or hydrogen bonds. Non-reversible inhibitor binding with enzyme is created through covalent bonding
by reacting chemically with the enzyme.
Request Sample Copy of this Market Research @
https://www.millioninsights.com/industry-reports/enzyme-inhibitor-market/request-sample
The market segmentation by inhibitor type into proton pump inhibitors (PPI), phosphodiesterase type
5 (PDE5) inhibitors, protease inhibitors, neuraminidase inhibitors, aromatase inhibitors, reverse
transcriptase inhibitor, statins, kinase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors.
These inhibitors have varied application in the pharmaceutical industry on the basis of reaction with
the pathogens such as PPIs for reducing the long lasting production of gastric acid, PDE5 to treat the
erectile dysfunction, protease for the treatment of HIV/AIDS, kinase to block the action of protein
kinases, reverse transcriptase to generate complementary DNA, neuraminidase to block the influenza
virus, statins for reducing the cholesterol production, and angiotensin for the treatment of
hypertension.